HRP20050242A2 - Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs - Google Patents

Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs

Info

Publication number
HRP20050242A2
HRP20050242A2 HR20050242A HRP20050242A HRP20050242A2 HR P20050242 A2 HRP20050242 A2 HR P20050242A2 HR 20050242 A HR20050242 A HR 20050242A HR P20050242 A HRP20050242 A HR P20050242A HR P20050242 A2 HRP20050242 A2 HR P20050242A2
Authority
HR
Croatia
Prior art keywords
amino acids
adamantane
unnatural amino
synthetic peptides
peptides containing
Prior art date
Application number
HR20050242A
Other languages
Croatian (hr)
Inventor
Horvat Štefica
Majerski Kata
Glavaš-Obrovac Ljubica
Jakas Andreja
Veljković Jelena
Roščić Maja
Kragol Goran
Karner Ivan
Original Assignee
Institut Ruđer Bošković
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Ruđer Bošković filed Critical Institut Ruđer Bošković
Priority to HR20050242A priority Critical patent/HRP20050242B1/en
Priority to PCT/HR2005/000031 priority patent/WO2006097774A1/en
Publication of HRP20050242A2 publication Critical patent/HRP20050242A2/en
Publication of HRP20050242B1 publication Critical patent/HRP20050242B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Sadašnji se izum odnosi na: (a) nove sintetske pentapeptidne analoge metionin-enkefalina i njegove strukturno srodne dipeptidne, tripeptidne, tetrapeptidne i heksapeptidne derivate koji obuhvaćaju neprirodne aminokiseline predstavljene Formulom W-X,gdje W i X imaju različita ovdje određena značenja; (b) na njihove farmaceutski prihvatljive soli isolvate; (c) na procese i međuprodukte za njihovupripravu; (d) na uporabu prirodnih i neprirodnih aminokiselina u pripravi novih peptida; pri čemu neprirodne aminokiseline sadrže adamantanski ostatak; (e) na njihovu primjenu kao protutumorskih lijekova za tretiranje različitih malignih oboljenja istanja kod ljudi i životinja.The present invention relates to: (a) novel synthetic pentapeptide analogs of methionine enkephalin and its structurally related dipeptide, tripeptide, tetrapeptide and hexapeptide derivatives comprising the unnatural amino acids represented by Formula W-X, wherein W and X have different meanings as defined herein; (b) to their pharmaceutically acceptable salts isolates; (c) the processes and intermediates for their preparation; (d) the use of natural and unnatural amino acids in the preparation of new peptides; wherein the unnatural amino acids contain an adamantane residue; (e) their use as antitumor drugs for the treatment of various malignancies in humans and animals.

HR20050242A 2005-03-15 2005-03-15 Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs HRP20050242B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HR20050242A HRP20050242B1 (en) 2005-03-15 2005-03-15 Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs
PCT/HR2005/000031 WO2006097774A1 (en) 2005-03-15 2005-05-13 Synthetic peptides containing unnatural adamantane-related amino acids for use as antitumour drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20050242A HRP20050242B1 (en) 2005-03-15 2005-03-15 Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs

Publications (2)

Publication Number Publication Date
HRP20050242A2 true HRP20050242A2 (en) 2007-02-28
HRP20050242B1 HRP20050242B1 (en) 2010-09-30

Family

ID=35229865

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050242A HRP20050242B1 (en) 2005-03-15 2005-03-15 Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs

Country Status (2)

Country Link
HR (1) HRP20050242B1 (en)
WO (1) WO2006097774A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399926A1 (en) 2010-06-22 2011-12-28 Justus-Liebig-Universität Giessen Peptides incorporating 3-aminoadamantane carboxylic acids enhance synaptic plasticity and act as neurogenic agents
CN104230935A (en) * 2011-04-26 2014-12-24 辽宁利锋科技开发有限公司 Anti-tumor effect and application of compound containing alicyclic structure
CN102241678B (en) * 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 Antitumor effect and application of alicyclic structure-containing compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8005121A (en) * 1979-09-20 1981-03-24 Erba Farmitalia ORGANICALLY ACTIVE PEPTIDES.
US4273704A (en) * 1979-12-03 1981-06-16 G. D. Searle & Co. N-Adamantane-substituted tetrapeptide amides

Also Published As

Publication number Publication date
HRP20050242B1 (en) 2010-09-30
WO2006097774A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
JP2013511553A5 (en)
ES2415756T3 (en) Enzyme inhibition compounds
US9206232B2 (en) Organic compounds and their uses
AR062801A2 (en) PEPTIDES RELEASING THE GROWTH HORMONE
IL232501A0 (en) Stable analogs of peptide and polypeptide therapeutics
DE602005008996D1 (en) RADIOFLUORATED PEPTIDES
JP2013511554A5 (en)
JP2013155195A5 (en)
RS54215B1 (en) Compositions and methods for diagnosing and treating cancer
RU2009100884A (en) PEPTIDE FRAGMENTS FOR INDUCTION OF PROTEIN SYNTHESIS OF EXTRACELLULAR MATRIX
ATE254630T1 (en) CYCLOSPORINS
DE69943130D1 (en) CYCTOTOXIC PEPTIDES MODIFIED WITH VOLUMINOUS OR LIPOPHILIC GROUPS
RU2014148530A (en) DIPEPTIDE DERIVATIVES LYSINE-GLUTAMIN ACID
JP2012529433A5 (en)
EA201491155A1 (en) NEW MUTANT PRO-NRF AND THEIR APPLICATION TO GET BETA-NRF
DE602004001727D1 (en) PROCESS FOR PREPARING CYCLIC PEPTIDES
CA2602755A1 (en) Antibacterial amide-macrocycles v
RU2012121562A (en) COMBINATION FOR TREATMENT OF MUKOZITE INDUCED BY IRRADIATION OR CHEMOTHERAPY
RU2010111139A (en) COMBINED THERAPY OF PANCREAS CANCER USING ANTIGENOUS PEPTIDE AND CHEMOTHERAPEUTIC
JP2007526254A5 (en)
HRP20050242A2 (en) Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs
SG11201902818PA (en) Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
Dębowski et al. Inhibition of human and yeast 20S proteasome by analogues of trypsin inhibitor SFTI-1
TW200722097A (en) Aqueous inhalation pharmaceutical composition
BRPI0511831A (en) peptide synthesis method

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150310

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20160315